Capricor Therapeutics

This weekend at the American Heart Association Scientific Sessions 2026, Dr. Jonathan Soslow of Vanderbilt received the Outstanding Research Award in Pediatric Cardiology for his presentation of the HOPE-3 cardiac results for Deramiocel in Duchenne muscular dystrophy. Congratulations, Dr. Soslow, and thank you to the patients, families and investigators who made this research possible.
Read the press release: bit.ly/4BMIYM5
#AHA26 #Duchenne #DMD #ScientificSessions26 #Deramiocel $CAPR

Capricor will report its third quarter 2026 financial results after market close on Tuesday, November 10, and host a conference call and webcast at 4:30 p.m. ET. Register: bit.ly/4yUwIGA $CAPR

Today at 1:00 p.m. ET, Capricor and @PPMD are hosting a webinar on the latest HOPE-3 open-label extension 2-year results, presented last week at the World Muscle Society Congress in Japan.
We will walk through the data in more detail and discuss what these results may mean for the Duchenne muscular dystrophy community.
Register here: bit.ly/3Ubm3c8
$CAPR #Deramiocel #PPMD #Duchenne #DMD

Capricor today announced new 24-month data from the HOPE-3 open-label extension, presented last week in a late-breaking poster at the 2026 World Muscle Society Congress in Hiroshima, Japan.
Patients who began Deramiocel after a year on placebo experienced a 76% reduction in their rate of upper limb decline compared with their own prior year. At 24 months, both treatment groups had declined less than natural history predicts.
Read the full press release: bit.ly/4ANTtOD

#Duchenne #DMD #WMS2026 #Deramiocel $CAPR

Capricor is headed to the 2026 World Muscle Society Congress in Hiroshima, Japan, September 29 – October 3.

We’re looking forward to sharing new HOPE-3 open-label extension data for Deramiocel in Duchenne muscular dystrophy, including skeletal muscle and cardiac outcomes through 24 months. Dr. Craig McDonald of UC Davis will present the findings in a late-breaking poster and an oral presentation, alongside additional research from our StealthX™ platform exploring muscle-targeting extracellular vesicle technologies.

We’re proud to continue advancing the science and working toward better options for boys and families living with Duchenne. 💙

Read more: bit.ly/3TFiBWZ

$CAPR #Deramiocel #Duchenne #DMD #exosomes #WMS2026 #WorldMuscleSociety